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Does Naloxone Reinstate Secondary Hyperalgesia in
Humans after Resolution of a Burn Injury? A PlaceboControlled, Double-Blind, Randomized, Cross-Over Study
Manuel P. Pereira1,2*, Mads U. Werner1, Thomas K. Ringsted1, Michael C. Rowbotham3, Bradley K. Taylor4,
Joergen B. Dahl2
1 Multidisciplinary Pain Center, Neuroscience Center, Rigshospitalet, Copenhagen University Hospitals, Copenhagen, Denmark, 2 Department of Anaesthesia, Centre of
Head and Orthopaedics, Copenhagen University Hospitals, Rigshospitalet, Copenhagen, Denmark, 3 California Pacific Medical Center Research Institute, San Francisco,
California, United States of America, 4 Department of Physiology, University of Kentucky Medical Center, Lexington, Kentucky, United States of America

Abstract
Introduction: Development of secondary hyperalgesia following a cutaneous injury is a centrally mediated, robust
phenomenon. The pathophysiological role of endogenous opioid signalling to the development of hyperalgesia is unclear.
Recent animal studies, carried out after the resolution of inflammatory pain, have demonstrated reinstatement of tactile
hypersensitivity following administration of m-opioid-receptor-antagonists. In the present study in humans, we analyzed the
effect of naloxone when given after the resolution of secondary hyperalgesia following a first-degree burn injury.
Methods: Twenty-two healthy volunteers were included in this placebo-controlled, randomized, double-blind, cross-over
study. Following baseline assessment of thermal and mechanical thresholds, a first-degree burn injury (BI; 47uC, 7 minutes,
thermode area 12.5 cm2) was induced on the lower leg. Secondary hyperalgesia areas around the BI-area, and separately
produced by brief thermal sensitization on the contralateral thigh (BTS; 45uC, 3 minutes, area 12.5 cm2), were assessed using
a polyamide monofilament at pre-BI and 1, 2, and 3 hours post-BI. At 72 hrs, BI and BTS secondary hyperalgesia areas were
assessed prior to start of a 30 minutes intravenous infusion of naloxone (total dose 21 microg/kg) or placebo. Fifteen
minutes after start of the infusion, BI and BTS secondary hyperalgesia areas were reassessed, along with mechanical and
thermal thresholds.
Results: Secondary hyperalgesia areas were demonstrable in all volunteers 1–3 hrs post-BI, but were not demonstrable at
72 hrs post-burn in 73–86% of the subjects. Neither magnitude of secondary hyperalgesia areas nor the mechanical and
thermal thresholds were associated with naloxone-treated compared to placebo-treated subjects.
Conclusion: Naloxone (21 microg/kg) did not reinstate secondary hyperalgesia when administered 72 hours after a firstdegree burn injury and did not increase BTS-generated hyperalgesia. The negative results may be due to the low dose of
naloxone or insufficient tissue injury to generate latent sensitization.
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instatement of hypersensitivity to noxious stimuli near or at the
injured area [16–19]. It has been hypothesized that the
endogenous opioid-dependent mechanisms are responsible for
the transition from acute to chronic pain in humans [13,16,17].
Translational research, from animals to humans, in latent
sensitization is of critical importance, since insight in these
pathological mechanisms may lead to reformulation of strategies
for prevention of chronic pain.
A number of human sensitization models using capsaicin [20],
electrical stimulation [8], and thermal injury [2], have been used
to evaluate secondary hyperalgesia (i.e. hyperalgesia or allodynia
in normal skin surrounding the injury site), a centrally mediated
event [21,22]. Development of secondary hyperalgesia is modu-

Introduction
Considerable research effort has been invested in examining the
contribution of central sensitization [1] to development of chronic
pain [2–7]. In chronic pain conditions such as neuropathic pain,
fibromyalgia or chronic tension headache, the endogenous opioid
modulation of central sensitization is impaired or altered [2,8–12].
In experimental research in rodents, injury or exposure to
opioid may produce long-lasting vulnerability, termed latent
sensitization [13], to noxious stimuli [14,15], non-noxious
environmental stress stimuli [13,16], ultralow doses of opioid
[16] and opioid antagonists [17–19]. Administration of naloxone
and naltrexone to animals, following resolution of an inflammatory
injury, has demonstrated a NMDA-receptor dependent rePLOS ONE | www.plosone.org
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participate in the study and they were familiarized with
assessments and the BI on their dominant leg. Day 1 and Day 3
were the BI-days separated by 72 hrs from Day 2 and Day 4
which were the drug administration days. Between Day 1 and Day
3 there was a wash-out period of 3–4 weeks. If volunteers received
naloxone on Day 2, they would then get placebo on Day 4 and
vice-versa.

lated by various drugs: adenosine [23], gabapentin [24], glucocorticoids [25], NMDAR (N-Methyl-D-aspartate-receptor) blockers [26,27], and opioids [28–30]. However, the effects of naloxone
per se on secondary hyperalgesia areas are more ambiguous
[2,8,31–33].
In the present study, we used a first-degree burn injury (BI) as a
validated inflammatory model of sensitization [34,35]. The
primary aim was to examine if naloxone could re-instate
secondary hyperalgesia areas after resolution of the thermal
injury. The secondary aim was to examine the effect of naloxone
on secondary hyperalgesia areas produced by brief thermal
sensitization on the contralateral thigh (BTS) and, on thermal
and mechanical thresholds in the primary hyperalgesia area.

Randomization Procedure
The randomization procedure was performed by a research
nurse not participating in the study. A total of 28 subject-numbers
were randomly allocated into two groups (A and B) using a
randomization software (randomisation.com). Groups A and B
were randomized to start with either naloxone or placebo. For
each subject-number the randomization code was included in a
non-transparent envelope. The envelope and 6 ampoules of
naloxone 0.4 mg/ml (Naloxon "B. Braun", B. Braun Melsungen,
Germany), were packed for each subject-number in an opaque
sealed box.
The infusions were prepared up to 8 hrs before the study session
by a research nurse or physician, not participating in the study and
not employed in the department. The naloxone infusion was
prepared by diluting 6 ml of naloxone 0.4 mg/ml with 154 ml
normal saline, obtaining a concentration of naloxone 15 microg/
ml. The placebo infusion was normal saline in an identical volume,
160 ml. The individual randomization codes for each session were
returned into the respective envelope, and empty or unused
ampoules were returned to the box, which then was resealed.
There was no contact between the research nurse and the
physician preparing the infusions, and, the investigators.

Methods
Volunteers
The study protocol was approved by The Committees on
Health Research of the Capital Region of Denmark and the
Danish Medicines Agency (Protocol no.: H-2-2012-036, EudraCT
nr.: 2012-000839-54). The study was conducted according to the
principles of Good Clinical Practice (GCP), and monitored by the
Copenhagen University Hospitals’ GCP-unit. Healthy volunteers
were recruited to participate in this study through flyers and
advertisements at campuses at Copenhagen University, or from
own records from completed studies. Twenty three volunteers
were screened for eligibility. Inclusion and exclusion criteria are
presented in Table 1. All volunteers were provided information
regarding the study and its possible risks and signed a written
consent. The volunteers were paid EUR 300 (USD 385) as a
compensation for their participation in the study.

Setting

Study Design

Environment. The experimental procedures were performed
in a quiet, bright room with a temperature 24–27uC and a relative
humidity (RH) of 30–63%. The testing sessions were made
between June 12th and August 16th 2012, and were carried out
Mondays to Fridays between 07.30 AM and 08.00 PM. Subjects
adopted a comfortable supine position during the assessments, and

The study followed a placebo-controlled, double-blind, randomized, cross-over design.

Study Algorithm
The study was performed on 5 separate days (Figs. 1 and 2). On
Day 0 volunteers were screened whether they were eligible to
Table 1. Inclusion and exclusion criteria.

Inclusion Criteria

Exclusion Criteria

N ASA I-II

N not cooperative

N 20# age #35 years

N not understand or speak Danish or English

N urine sampled negative for amphetamines, barbiturates,
benzodiazepines, cocaine, opioids (buprenorphine, methadone,
morphine) and tetra-hydrocannabinol (THC)

N pregnancy, breastfeeding, planning pregnancy or who were not using contraceptives
(pill or IUD)

N 18 kg/m2, BMI and ,30 kg/m2

N participated in a drug trial in the previous 60 days
N alcohol or drug abuse
N use of psycho-active drugs or analgesics
N neurological illness
N chronic pain condition
N allergy to morphine or naloxone
N skin lesions on the measurement areas
N signs of a neuropathy in the ipsilateral or contralateral measurement areas
N prescription drugs 1 week before the trial
N over-the–counter medication 48 hours before the test

doi:10.1371/journal.pone.0064608.t001
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assessments were made in triplicate and the mean value was used
in further analyses. Thermal thresholds were assessed at baseline
and 73 hrs. after the BI (Fig. 2).
Burn injury. The first-degree BI was induced with a contact
thermode (Thermotest, Somedic AB, Hörby, Sweden (12.5 cm2,
47.0uC, 7 minutes)). The pain intensity during the BI was rated on
a visual analog scale (VAS (0 = no pain, 100 = maximum
imaginable pain)) at 0, 30, 60, 120, 180, 240, 300, 360 and 420
seconds after the thermode had reached 47.0uC.
Brief thermal sensitization (BTS). The application area
was delineated on the skin, with the lower border of the rectangle
11 cm superior to the upper border of the patella in the mid line.
A noxious tonic heat stimulus of 45uC was delivered to the anterior
side of the dominant thigh using the contact thermode, as
previously described [24,38]. After a 180 s stimulation period, the
area of secondary hyperalgesia was assessed using a polyamide
monofilament (nominal value 18 (890650 mN (mean6SD)),
Stoelting, IL, USA) [37] with the heated thermode in situ. Heat
stimulation was limited to a maximum of 300 seconds. The BTS
assessments were performed on Day 1 and Day 3 at baseline, and
1, 2, and 3 hours post-burn. On Day 2 and Day 4, assessments
were made before and during the infusions at 72 and 73 hours
post-burn (PB).
Secondary hyperalgesia areas were assessed using a polyamide
monofilament (nominal value 18). The border was determined by
stimulating in 8 symmetric lines each separated by an angle of 45̊
converging towards the centre of the burn injury. The stimulations
started in normal skin outside the area of secondary hyperalgesia
and the subjects, who had their eyes closed during the assessments,
reported the occurrence of a definite change in sensation, to an
uncomfortable, burning or stinging sensation. The corners of the
octagon were marked on the skin and transferred to a transparent
sheet. The secondary hyperalgesia areas were calculated (total area
- area of the thermode) using a computer-based vector-algorithm
(Canvas 12.0, ACD Systems International, Victoria, Canada).
Assessments of secondary hyperalgesia areas on Day 1 and Day
3 were done at baseline, and, 1, 2 and 3 hours PB. On Day 2 and
Day 4 assessments of secondary hyperalgesia areas were made
before the infusions at 72 hours PB and during the infusions at 73
hours PB.

Figure 1. Study algorithm. The study was performed on 5 separate
days. Day 0 corresponded to the screening day; Day 1 and Day 3 were
the burn injury days separated by 72 hrs from the drug administration
days, Day 2 and Day 4.
doi:10.1371/journal.pone.0064608.g001

were allowed to move freely in adjacent rooms between the
assessments.
Pin-prick thresholds. The area for quantitative sensory
testing (QST) was the upper, medial part of the non-dominant
lower leg. The subjects were instructed to use a hair-trimmer in
the area, 2 days before the study days, in order to avoid
interference with the sensory assessments. The rectangular BI
area, 2.565.0 cm2, was delineated with the upper anterior corner
11 cm below the medial meniscus margin and 6 cm from the
anterior margin of the tibia.
Pin-prick pain thresholds (PPT) were assessed by weighted-pin
stimulators (PinPrick, MRC Systems, Heidelberg, Germany (8, 16,
32, 64, 128, 256, 512 mN)) with a contact-area of 0.31 mm2. Five
assessments were performed according to Dixon’s ‘‘up-and-down’’
method [36]. Volunteers were stimulated 5 times at the site of the
BI and were asked to indicate when $3 of the pin-pricks were
perceived as painful. Using pin-prick stimulators of ascending or
descending order, the PPT was determined 5 times and the
median of these assessments was then considered for analysis. PPT
assessments were performed at all study days.
Thermal thresholds. Warmth detection threshold (WDT)
and heat pain threshold (HPT) were assessed in the BI area by a
contact thermode (Thermotest, Somedic AB, Hörby, Sweden
(12.5 cm2)), as previously described in detail [37]. The thresholds
were determined from a baseline temperature of 32uC with a ramp
rate of 1uC/s and 50uC was the cut-off temperature. The
PLOS ONE | www.plosone.org

Drugs
On Day 2 and Day 4 (Figs. 1 and 2) a 30 minutes intravenous,
target-controlled infusion of naloxone 15 microg/ml or placebo
was administered starting 72 hrs 45 minutes after the BI [8]. An
i.v. bolus of naloxone was administered (5 microg/kg) during 2
minutes, followed by an infusion at rate of 40 microg/kg/h for 20
minutes and finally, at a rate of 20 microg/kg/h for 8 minutes [8].
Thus, volunteers were given a total 21 microg/kg of naloxone over
30 minutes. Identical administration volumes (1.4 ml/kg) and
algorithm was used for placebo-infusion [8].

Statistics
Estimating the sample size, a significance level of 0.01 (a), a
power of 0.9 (b = 0.1), an intra-individual standard deviation (SD)
of secondary hyperalgesia areas at 72 hrs after the burn injury, of
5 cm2, and a minimal relevant difference 5 cm2 were used. Since
no data are available in regard to these estimates,(this is the first
study in this area) we used estimates that were considered relevant
for the sample size calculation. Under the assumptions that data
would be normally distributed and that the study had a cross-over
design, the estimated number of subjects needed were 19.
However, in order to compensate for any drop-outs, the number
of volunteers was set to 22.
3
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Figure 2. Detailed timetable algorithm of the study. (Study Days 1 and 2, and, Study Days 3 and 4 are identical). BL = baseline (warmth
detection thresholds, heat pain thresholds, pinprick pain thresholds, secondary hyperalgesia areas in brief thermal stimulation and burn injury sites),
Nx-INF = Naloxone target-controlled infusion (see text for detailed explanation). 1/2/3 PB = postburn assessments 1, 2 and 3 hrs after the burn injury
(secondary hyperalgesia areas on brief thermal stimulation and burn injury sites), 72 PB = postburn assessments 72 hrs after the burn injury (pinprick
pain thresholds, secondary hyperalgesia areas on brief thermal stimulation and burn injury sites), 73 PB = postburn assessments 73 hrs after the burn
injury (warmth detection thresholds, heat pain thresholds, pinprick pain thresholds, secondary hyperalgesia areas on brief thermal stimulation and
burn injury sites).
doi:10.1371/journal.pone.0064608.g002

To test if data was normally distributed, the KolmogorovSmirnov test and residual plots were used. In case of non-normal
distribution, a logarithmic transformation was tried for normalization of the data. Paired t–test was used for comparison in case of
normally distributed data, whereas Wilcoxon rank sum test was
used for non-normally distributed data. Fisher’s exact test was used
in the analysis 262 contingency tables. A P-value of 0.01 was
assigned as the significance level.
After completion of the study, data was first partially unblinded
for statistical analyses: subjects were divided into group A and B
(see Randomization Procedure). Only after completion of the
statistical analyses, data were fully unblinded.
Data are given as mean (SD) or median (25–75% interquartile
range [IQR]).

The Burn Injury
Pain during induction. The volunteers described mild to
moderate pain during the 7 minutes burn with VAS/minute ratings Day 1:30.462.3 and Day 2:28.861.5. No statistically
significant habituation effect, i.e. decrease of perceived pain
intensity throughout the study days, was observed between Day 1
and Day 3 (P = 0.21 [Table 3]).
Local skin changes. Erythema and hyperalgesia were seen
in all volunteers following the BI. No residual effects related to the
BI were observed, with the exception of one volunteer (#14), who
developed small areas of hyperpigmentation at the injury-site 23
days after the BI. No blisters were observed.
Secondary hyperalgesia areas. Secondary hyperalgesia
areas were observed in all volunteers, in both baseline assessment
days (Day 1 and 3), with the exception of one volunteer (#12),
who did not develop a measurable area in one of the days (Day 3).
Secondary hyperalgesia areas were significantly larger on Day 1
compared to Day 3 (P,0.01), indicating a habituation effect. On
Days 2 and 4, three volunteers had detectable secondary
hyperalgesia areas before infusion of naloxone, and 6 volunteers
before infusion of placebo (P = 0.46). Nine volunteers developed
larger areas of secondary hyperalgesia after receiving naloxone
compared to placebo, whereas 13 volunteers developed (larger)
secondary hyperalgesia areas after placebo infusion compared to
naloxone [Fig. 3]). However, when comparing both distributions which is the primary endpoint of this study - there were no
significant changes in the magnitude of hyperalgesia areas
following naloxone or placebo (P = 0.25).
There was an agreement between BI and BTS data (below) in
regard to changes in secondary hyperalgesia areas with administration of naloxone when compared to placebo: the sign-test
showed that 16 volunteers had congruent findings with both
methods, while 6 volunteers had different findings.

Results
Demographic Data
A total of 23 volunteers were included in the study. However,
one volunteer (#4) was excluded, due to participation in another
study less than 60 days before. Thus, per-protocol data from 22
healthy volunteers (11 females, 11 males) were included in the
present study. Demographic data are illustrated in Table 2.

Table 2. Demographic data.

n

Age (yrs)

Height (cm)

Weight (kg)

Male

11

24.562.0

181.363.3

77.766.9

Female

11

23.061.2

172.265.0

66.766.4

Mean values6SD.
doi:10.1371/journal.pone.0064608.t002
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Table 3. Cumulative VAS scores (0–100).

Day 1

Day 2

Cumulative VAS

VAS/minute ± SD

Cumulative VAS

VAS/minute ± SD

Burn-injury

5348

30.462.30

–

–

BTS

767

8.761.47

462

5.360.88

Burn-injury

5068

28.861.47

–

–

BTS

627

7.260.99

462

5.360.23

Day 3

Day 4

VAS/minute and standard deviation reported by the volunteers during the burn injury (Day 1+3) and BTS (Day 1+2+3+4). No difference in cumulative VAS was observed
between Day 1 and 3 during the burn injury (P = 0.21) and during BTS (P = 0.09). There was a significant difference between Day 1 and 2 (P,0.01), and Day 3 and 4 in
VAS ratings during BTS (P,0.05). BTS = Brief thermal stimulation.
doi:10.1371/journal.pone.0064608.t003

Local skin changes. Erythema and hyperalgesia were seen
in all volunteers following BTS. No blisters or other residual effects
were observed.
Secondary hyperalgesia areas. Development of secondary
hyperalgesia areas was observed in all volunteers following BTS.
Administration of naloxone was not associated with a change the
areas of the secondary hyperalgesia compared to placebo
(P = 0.76). Nine volunteers developed larger areas after infusion
of naloxone when compared to placebo, while 13 volunteers
developed larger areas after infusion of placebo compared to
naloxone (Fisher’s exact test, P = 0.37).

Brief Thermal Stimulation
The BTS procedure induced only a
mild pain, with low VAS-ratings (VAS/minute6SD) of 8.761.5
(Day 1), 5.360.9 (Day 2), 7.261.0 (Day 3) and 5.360.23 (Day 4),
(Table 3). Pain assessments were performed at baseline on Days 1
and 3, and then again 72 hours post-burn on Days 2 and 4. No
statistically significant habituation effect was evident between Days
1 and 3 (P = 0.09). However, there was a significant habituation
effect between Day 1 and Day 2 (P,0.01) with lower values on
Day 2. A similar effect was seen between Day 3 and Day 4
(P,0.05) [39].
Pain during induction.

Figure 3. Size of secondary hyperalgesia areas after naloxone or placebo administration. Individual secondary hyperalgesia areas (nvalues = post-infusion area – pre-infusion area) at burn injury site in cm2 after administration of naloxone and placebo, 72 hrs post-burn. The median
(25–75% interquartile range) change in secondary hyperalgesia areas after naloxone administration was 1.87 cm2 (0.74–7.00) and after placebo
administration 3.10 cm2 (1.48–11.42). Magnitude of secondary hyperalgesia areas was not associated with naloxone-treated compared to placebotreated subjects (P = 0.25).
doi:10.1371/journal.pone.0064608.g003
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phenomenon has a different underlying mechanism or is expressed
differently.

There was an interval of 23.062.2 days between Day 1 and Day
3. This interval was associated with a habituation in induction of
hyperalgesia areas, i.e. significantly larger areas on Day 1 were
observed when compared to Day 3 (P,0.01) [39].

Mechanisms of Latent Sensitization in Animals
Intraplantar injection of complete Freund’s adjuvant (CFA) in
mice produces mechanical hypersensitivity, evidenced by a
reduction in tactile thresholds [18,19]. Following complete
resolution of the hypersensitivity, 21 days after the injury,
intrathecal or systemic administration of naltrexone or CTAP
(MOR-selective antagonist), is associated with reinstatement of
mechanical hypersensitivity [19]. Intrathecal administration of
pertussis toxin, destroying G-a-subunit (Gai/o)-proteins, also leads
to a reinstatement of mechanical hypersensitivity, suggesting a
tonic activity of inhibitory GPCRs (G Protein-Coupled Receptors)
signalling [18,19]. Pre-treatment with MK-801 (Dizocilpine), a
non-competitive NMDAR-blocker, prevents the reinstatement of
mechanical hypersensitivity, indicating that latent pain sensitization is dependent on NMDAR activity [18,19]. These studies
suggest that NMDAR-activity regulates a form of spinal sensitization that persists long after the resolution of inflammatory
hyperalgesia. An up-regulated, tonic activation of opioid receptors,
functionally coupled to Gai/o-proteins, prevents this spinal
sensitization from remaining clinically apparent until an opioid
receptor blocking agent is administered.

Mechanical Thresholds
The PPT, assessed in the BI-area, did not change with
administration of naloxone when compared to placebo (P = 0.98,
[Table 4]).

Thermal Thresholds
There were no significant differences in WDT and HPT,
assessed in the BI-area, between Day 1 and 2 ([baseline vs. 73 hrs
PB, Fig. 2] P = 0.10, P = 0.27, respectively), and between Day 3
and 4 (P = 0.13, P = 0.12, respectively [Table 4]). Naloxone
administration was not associated with changes in WDT
(P = 0.39) or HPT (P = 0.21), when compared to placebo.

Adverse Drug-related Effects
No drug-related adverse effects were observed in this study.

Discussion
In the present placebo-controlled, crossover study in humans,
we were not able to demonstrate naloxone-mediated reinstatement
of secondary hyperalgesia areas following resolution of a firstdegree thermal burn injury (BI). Naloxone changed neither
secondary hyperalgesia produced by BTS nor mechanical or
thermal thresholds in the primary hyperalgesia area. There are
several possible reasons why the present study in humans did not
produce the same results as earlier studies in rodents. First, the dose
of naloxone may have been too low. Second, the superficial thermal
injury, producing only limited tissue injury, may have been
deficient for generating latent sensitization. Third, the time point
chosen for looking for latent sensitization may have been incorrect.
In animals, the situation is different with naloxone robustly
reinstating secondary hyperalgesia long after a primary injury has
apparently healed. Fourth, methodological inadequacies may have
been present. Fifth, species differences may be such that the

Naloxone Dose
The effective systemic doses of opioid antagonists used in animal
studies to demonstrate latent sensitization have been 1 mg/kg of
naloxone [17] or 0.3 to 3.0 mg/kg of naltrexone (unpublished
studies, Taylor BK). Estimates of equipotency of naltrexone and
naloxone depend on route of administration and the pharmacodynamic efficacy measure: antagonism of opioid analgesia,
reversal of opioid-induced ventilatory depression, precipitation of
withdrawal symptoms or inhibition of discriminative effects of
opioids [40]. The available estimates from animal studies indicate
a 2–4 higher potency for systemically administered naltrexone
compared to naloxone [41,42]. The dose of naloxone 0.021 mg/
kg used in the present study is much lower than in the animal
studies, and could therefore explain our failure to demonstrate
latent sensitization.

Table 4. WDT, WDT and PPT.

Day 1

Day 2
Pre-Inf

Post-Inf

n(Day 2post–Day1)

WDT (uC)

4.4161.56

–

4.8061.64

0.4061.39 (P = 0.10)

HPT (uC)

44.5962.34

–

44.0262.50

20.5762.37 (P = 0.27)

PPT (mN)

512 [512;513]

512 [256;512]

512 [128;512]

–

Day 3

Day 4
Pre-Inf

Post-Inf

n(Day 4post -Day3)

WDT (uC)

4.8962.11

–

5.1162.23

0.2361.58 (P = 0.13)

HPT (uC)

44.9062.19

–

44.4962.56

20.4161.61 (P = 0.12)

PPT (mN)

512 [256;513]

512 [256;512]

256 [256;512]

–

Mean value and standard deviation of WDT and HPT are shown in this table, as well as median values and 25–75% IQR of PPT. On Day 2 and 4, pin-prick assessments
were performed before and after i.v. administration of naloxone or placebo, whereas HPT and WDT were only assessed after drug infusion. Naloxone administration was
not associated with changes in WDT (P = 0.39), HPT (P = 0.21) and PPT (P = 0.98). There were no significant differences in WDT and HPT, assessed in the BI-area, between
Day 1 and 2 ([baseline vs. 73 hrs PB, Fig. 2] P = 0.10, P = 0.27, respectively), and between Day 3 and 4 (P = 0.13, P = 0.12, respectively).
HPT = Heat pain thresholds, PPT = Pin-prick thresholds, WDT = Warmth detection thresholds.
doi:10.1371/journal.pone.0064608.t004
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In the present study, a target-controlled infusion, corresponding
to an estimated plasma naloxone concentration of 10 ng/mL, was
used. This dose regimen is identical to a study with intradermal,
high current-density electrical stimulation, which demonstrated
significant increases in established secondary hyperalgesia area
following naloxone administration [8]. However, the high currentdensity stimulation is administered over a longer time period and
is both more painful than BI and BTS and persists as long as the
electrical stimulation continues. The increased magnitude of
established secondary hyperalgesia, during ongoing electrical
stimulation, by administering naloxone, is evidence that the
inhibitory endogenous opioid system is immediately activated and
thus not analogous to the experimental paradigm used in the
present study.
A number of human hyperalgesia studies [2,32,33,43] have used
higher doses of naloxone, up to 0.1 to 0.2 mg/kg, without
demonstrating any hyperalgesic effects during other types of acute
experimental pain. High doses of 1–2 mg/kg of naloxone have
been used in clinical and experimental psychiatric, endocrinological, neurological or nutritional studies in patients [44–49] and in
healthy volunteers [50–54]; however, this dose-range has not been
used in human pain research. A Positron Emission Tomography
study in volunteers with naloxone 0.1 mg/kg demonstrated a
complete inhibition of the binding of a potent MOR-agonist
carfentanil [55]. It is tempting to speculate that higher doses of
opioid antagonists might be needed to sufficiently block the
endogenous opioid system and allow latent sensitization to become
apparent.

compared to smaller monofilaments of 200–300 mN [59]. These
smaller monofilaments probably delineate much larger areas of
hyperesthesia and allodynia, but not hyperalgesia [59].
In the rodent studies [18,19] mechanical hypersensitivity was
assessed by thresholds to monofilament stimulation, while in the
present study changes in mechanical hypersensitivity were
evaluated by pin-prick assessments of secondary hyperalgesia
areas. These grading methods of hypersensitivity are clearly
different, i.e. one method measures thresholds while the other
measures areas. However, in humans the methods are inversely
interrelated: increased sensitivity in the secondary hyperalgesia
area, following a burn injury, is associated with a proportional
decrease in mechanical pain thresholds and an increase in
secondary hyperalgesia areas [60–62].
A methodological advantage of the present study was that 2
separate methods of secondary hyperalgesia area assessments, i.e.
the BI- and BTS-methods, were used. Changes in hyperalgesia
area after naloxone or placebo administration showed a high
degree of agreement between the two methods; the same direction
of change was observed in 16 out of 22 volunteers. However, it
should be emphasized that the two methods differ in regard to
induction of secondary hyperalgesia areas: in the BI-method reinstatement of secondary hyperalgesia following resolution of an
injury was examined and with the BTS-method the response to an
acute noxious stimulus was analysed.
Habituation. Habituation effects between the first BI (Day 1)
and the second BI (Day 3), was seen in regard to secondary
hyperalgesia areas, but not in regard to other variables tested. This
effect has been reported before and thus was expected [35,37].
However, any confounding is minimized by the randomization
and the cross-over design: results were similar regardless of
whether the volunteers were first given naloxone or placebo.
However, a longer interval between sessions might reduce any
habituation effect.

Extent of Injury
The animal studies of latent sensitization with the plantar
incision [17] and CFA [18,19] model, induce deep tissue
inflammation. These models are likely associated with an
increased degree of nociception compared to the superficial BImodel, which may be inadequate for generating latent sensitization. There are no studies examining the severity of the primary
injury and the latent sensitization. However, Maihöfner and coworkers showed activity in the pre-frontal cortex, secondary
somatosensory cortex, insular cortex, anterior cingulate cortex and
thalamus after repeated minor heat stimulation both at
46.760.4uC and 43.560.5_uC, (9 cm2, 15 s, left volar arm) [56]
and in a different study at 46.7uC62.0uC and 40.4uC61.9uC
(9 cm2, 24 s, left volar arm) [57], observations suggesting that even
mild heat stimuli are processed by rostral neural centers. There is
evidence that pain can induce changes in neuronal network
connectivity and in chronic pain patients structural brain changes
may occur [58].

Species Issue
Species differences may be such that the phenomenon has a
different underlying mechanism or is expressed differently. No
systematic research has directly compared latent sensitization
between humans and rodents. The models of hyperalgesia and
endpoints determined are quite different between the current
study and previous rodent studies. For example, while we
evaluated tactile hyperalgesia (response to pin) following a mild
burn injury, previous animal studies evaluated tactile allodynia
(response to von Frey hairs) following injection of an inflammogen
(Corder et al) [18,19] or incision plus opioid (Campillo et al)
[17,63]. Additional studies in animal models of mild burn injury
are required to determine whether the parameters used in the
current study are sufficient to induce latent sensitization in
animals.

Time from Injury to Attempted Reinstatement
The interval between injury and assessment of latent sensitization in the experimental animal studies has been 21 days [17–19].
In the present study, due to the more superficial inflammatory
injury, an interval of 3 days was used. Although no systematic
research has been made in regard to the minimal necessary
interval needed to show latent sensitization, it is possible that
evaluating a different interval between the injury and testing could
demonstrate latent sensitization.

Conclusion
In conclusion, although recent animal studies, based on an
inflammatory injury, have shown a late re-instatement of
secondary hyperalgesia following administration of an opioidantagonist, the present study could not reproduce these results in a
human first-degree burn injury model. The negative results might
be explained by use of a low dose of naloxone (leading to an
insufficient blockade of endogenous opioid receptors); the limited
tissue injury by the model; incorrect timing of assessments relative
to drug administration; or to species differences. Further studies
are needed to fully examine the possibility of latent sensitization
after injury in humans.

Methodological Issues
Assessment of secondary hyperalgesia areas. In the
present study, areas of secondary hyperalgesia areas were assessed
using a polyamide monofilament (nominal value 18, bending force
of 890 mN). This is a relatively large monofilament, which may
allow a more accurate assessment of hyperalgesia areas, when
PLOS ONE | www.plosone.org
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